嵌合抗原受体T细胞疗法在实体瘤中的研究进展  

Research progress of chimeric antigen receptor-T cell therapy in solid tumors

作　　者：王昌荣 苏亚珍 关勇宇 鲁彦[3] 刘芳 陈彻 WANG Changrong;SU Yazhen;GUAN Yongyu;LU Yan;LIU Fang;CHEN Che(School of Public Health,Gansu University of Chinese Medicine,Gansu Province,Lanzhou730000,China;Department of Clinical Laboratory,Gansu Provincial Maternity and Child-Care Hospital,Gansu Province,Lanzhou730050,China;Department of Clinical Laboratory,Gansu Provincial Hospital,Gansu Province,Lanzhou730000,China)

机构地区：[1]甘肃中医药大学公共卫生学院,甘肃兰州730000 [2]甘肃省妇幼保健院检验科,甘肃兰州730050 [3]甘肃省人民医院检验科,甘肃兰州730000

出　　处：《中国医药导报》2024年第28期62-66,71,共6页China Medical Herald

基　　金：甘肃省自然科学基金项目(23JRRA1282);甘肃省青年科技基金项目(22JR11RA124);甘肃省中医药研究中心开放课题(zyzx-2023-06);甘肃省兰州市科技计划项目(2023-2-12);甘肃中医药大学科学研究与创新基金项目(2022KCYB-2)。

摘　　要：嵌合抗原受体(CAR)是一种由基因工程人工合成的蛋白质分子,通过质粒、mRNA或病毒载体转染至T细胞中,最终显示在细胞表面形成CAR-T细胞。CAR-T细胞可特异性识别并以主要组织相容性复合体独立方式杀死肿瘤细胞。尽管CAR-T细胞疗法在治疗血液系统恶性肿瘤方面取得显著的临床效果,但仍有许多挑战限制其在实体肿瘤中的效果。本文综述CAR-T细胞疗法在提高实体瘤临床效果方面的最新进展及克服CAR-T细胞治疗实体瘤局限性的策略。Chimeric antigen receptor(CAR)is a protein molecule artificially synthesized by genetic engineering.It is transfected into T cells through plasmids,mRNA or viral vectors,and eventually displays on the cell surface to form CAR-T cells.CAR-T cell can specifically recognize and kill tumor cells in an major histocompatibility complex independent manner.Although CAR-T cell therapy has achieved remarkable clinical efficacy in the treatment of hematological malignancies,there are still many challenges that limit its therapeutic effect in solid tumors.This article reviews the latest progress in improving clinical efficacy of CAR-T cell therapy in solid tumors,as well as strategies to overcome the limitations of CAR-T cell therapy in solid tumors.

关 键 词：嵌合抗原受体T细胞 实体瘤 肿瘤免疫疗法 研究进展 

分 类 号：R73[医药卫生—肿瘤]